Eli Lilly reported top-line phase 3 Triumph-1 results for retatrutide, its weekly “triple-G” obesity candidate, showing weight loss across all tested doses in participants with overweight or obesity and cardiometabolic risk. Management also pointed to improvements in cardiovascular risk factors, with Lilly planning more detailed data for a later scientific meeting.